Patents Examined by Brian-Yong S. Kwon
  • Patent number: 7776882
    Abstract: The present invention is directed to 2-amino-3,4-dihydro-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: August 17, 2010
    Inventors: Ellen W. Baxter, Allen B. Reitz, Christopher John Creighton
  • Patent number: 7767700
    Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: August 3, 2010
    Assignee: Intermune, Inc.
    Inventor: Williamson Ziegler Bradford
  • Patent number: 7767682
    Abstract: Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: August 3, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Kathleen Keating Brown, Bonnie Blazer-Yost
  • Patent number: 7767702
    Abstract: The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: August 3, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Alexander Straub, Thomas Lampe, Josef Pernerstorfer, Elisabeth Perzborn, Jens Pohlmann, Susanne Röhrig, Karl-Heinz Schlemmer
  • Patent number: 7759360
    Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: July 20, 2010
    Assignee: Repros Therapeutics Inc.
    Inventor: Joseph S Podolski
  • Patent number: 7750041
    Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water ?0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: July 6, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Speck, Brunn Scheller
  • Patent number: 7750001
    Abstract: A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: July 6, 2010
    Assignee: Zenyaku Kogyo Kabushikikaisha
    Inventors: Kazuhiko Haruta, Shinichi Yaguchi, Toshiyuki Matsuno, Yoshio Tsuchida, Tetsuo Watanabe, Kimitomo Yoshioka, Ryogo Yui
  • Patent number: 7745455
    Abstract: Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound is a new therapeutic anti HIV option, in combination with another drug such as a NRTI or a protease inhibitor. It's heightened and sustained antiretroviral potency is due to the increased intracellular level of 3TC triphosphate, the active form of 3TC. This effect is obtained by combining 3TC, in usual doses, with a reduced dose of ddC, in the same pharmaceutical formulation. The product could be administered twice or even once daily, which is convenient, and does not increase the pill burden for the patient. The reduced ddC dosage prevents the occurrence of ddC related side effects. Other cytidine derivatives (racemic or negative enantiomers) could have the same effects as ddC and could probably be combined with 3TC, and have the same effect. On the other hand, low dose ddC may also increase the intracellular levels of other cytidine derivatives as it does for 3TC.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: June 29, 2010
    Inventor: Emil Toma
  • Patent number: 7745488
    Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: June 29, 2010
    Assignee: Prometic Biosciences, Inc.
    Inventors: Lyne Gagnon, Jean Barabe, Pierre Laurin, Christopher Penney, Boulos Zacharie
  • Patent number: 7745439
    Abstract: The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: June 29, 2010
    Assignees: Korea Research Institute of Chemical Technology, Jeil Pharm. Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, CJ Corp.
    Inventors: Hyae Gyeong Cheon, Sung-Eun Yoo, Sung Soo Kim, Sung-Don Yang, Kwang-Rok Kim, Sang Dal Rhee, Jin Hee Ahn, Seung Kyu Kang, Won Hoon Jung, Sung Dae Park, Nam Gee Kim, Sun Mee Kim, Kil Woong Mo, Jae Mok Lee, Hye Jung Kang, Koun Ho Lee, Jong Hoon Kim, Jeong-Hyung Lee, Seung Jun Kim
  • Patent number: 7745463
    Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: June 29, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Ying Han, John F. Kadow, Zhongxing Zhang, Nicholas A. Meanwell
  • Patent number: 7737185
    Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating wasting, especially a loss of muscle mass. The invention is also directed to methods for treating wasting in a patient with chronic obstructive pulmonary disorder. The present invention is also directed to methods for treating hypogonadism in males with chronic obstructive pulmonary disorder.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: June 15, 2010
    Assignee: Repros Therapeutics Inc.
    Inventors: Joseph S. Podolski, Ronald Wiehle
  • Patent number: 7736636
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of Nicotine, nicotinic acid analogs thereof, their combination with or without other pro-angiogenesis factors, vasodilator, or other therapeutic modalities to promote angiogenesis in the subject. This is composition and combination thereof is applicable to improving wound healing, erectile dysfunction, improving collateral or blood supply in patients with myocardial infarction, stroke, peripheral artery diseases, and other vascular disorders as disclosed.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: June 15, 2010
    Inventors: Shaker Mousa, Sarah Mousa
  • Patent number: 7723334
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 25, 2010
    Assignee: Pfizer Inc.
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
  • Patent number: 7709532
    Abstract: The present invention provides a method for improving the bioavailability of a renin inhibitor, preferably, of a ?-amino-?-hydroxy-?-aryl-alkanoic acid derivative, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, and an efflux protein inhibitor.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: May 4, 2010
    Assignee: Novartis AG
    Inventors: Gian P. Camenisch, Gerhard Gross, Isabel Ottinger, Daniel Wasmuth
  • Patent number: 7705011
    Abstract: An object of the present invention is to provide an agent for use in the effective treatment and prevention of endometriosis and uterine adenomyosis. The present invention relates to an agent for use in the treatment and prevention of endometriosis or uterine adenomyosis, comprising, as an active ingredient, a compound selected from the group consisting of 3-ethylpyridine, 3-methylpyridine, 2-ethylpyridine, and 2-methylpyridine.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: April 27, 2010
    Inventors: Masao Igarashi, Toshio Igarashi, Shigeo Igarashi
  • Patent number: 7704948
    Abstract: A stool softener and enteric coated bisacodyl form of a pharmaceutical composition.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: April 27, 2010
    Assignee: Euro-Celtique S.A.
    Inventors: Derek Allan Prater, Hassan Mohammed, Malcolm Walden, Geoff Hayes, Harjit Tamber
  • Patent number: 7700653
    Abstract: This invention relates to methods for treating cardiovascular disorders selected from heart failure, thromboembolic disorders, venous diseases, and fibriotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) wherein the several variables are as defined in the specification and claims.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: April 20, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Michael Härter, Michael G. Hahn, Claudia Hirth-Dietrich, Andreas Knorr, Elke Stahl, Johannes-Peter Stasch, Frank Wunder
  • Patent number: 7696236
    Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 13, 2010
    Assignee: InterMune, Inc.
    Inventor: Williamson Z. Bradford
  • Patent number: 7696251
    Abstract: A neuronal cell death induced by an oxidative glutamate toxicity is substantially inhibited by administrating to an mammal an effective amount of a phenylenediamine derivative compound of formula (I), wherein R is phenyl or butyl.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: April 13, 2010
    Assignee: Incorporated National University Iwate University
    Inventor: Takumi Satoh